What is Compass Therapeutics, Inc.'s (CMPX) StockRank?

MoatMap's StockRank for Compass Therapeutics, Inc. (CMPX) is 8/100, with a Strong Sell signal. This is a composite score combining Quality (39), Value (38), and Momentum (12) factor ranks across MoatMap's 19,000+ stock universe.

Does Compass Therapeutics, Inc. have an economic moat?

Compass Therapeutics, Inc. (CMPX) has a Quality factor score of 39/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Compass Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Compass Therapeutics, Inc. (CMPX) is Strong Sell, based on a StockRank of 8/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Compass Therapeutics, Inc. in?

Compass Therapeutics, Inc. (CMPX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

CMPX

STRONG SELLREMOVE

Compass Therapeutics, Inc. · Healthcare · United States · $348M · Avg Vol: $11M/d

StockRank

P/E (TTM)

—

ROE

-45.9%

D/E

0.1x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Compass Therapeutics is a clinical-stage oncology biotech with high cash burn. It does not possess the validated manufacturing scale or pricing power of a high-moat CDMO, failing our quality filters.

COMPANY DESCRIPTION

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing proprietary antibody-based therapeutics to treat cancer. The company utilizes its proprietary discovery platforms to target the human immune synapse, generating a pipeline of multi-specific candidates. Its competitive moat is anchored by its advanced antibody engineering capabilities and its promising lead oncology candidates in clinical trials.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	850,000	0	—
EPS	-0.37	-0.33	-0.36	-0.42	—
Shares	126M	128M	138M	178M	+41.2%
Debt	3M	2M	7M	10M	49.6%
Equity	182M	149M	125M	197M	2.7%
Op CF	-34M	-41M	-45M	-49M	—
Inv CF	-151M	27M	47M	-93M	—
Fin CF	76M	3M	17M	130M	—

PRICE (1M)+5.2%

SMA 50SMA 200

$2.04

RSI (14)

42.0

52W High

$6.88

From 52W High

0.3%

SCORE BREAKDOWN

Quality

ROIC

-35.4%19.3

ROE

-45.9%19.2

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-13.7%23.7

Piotroski

—28.8

Int. Cover

—N/A

D/E Ratio

0.05x73.7

Current Ratio

19.04x94.9

Value

P/E (TTM)

—N/A

EV/EBITDA

-2.4x68.2

P/FCF

—N/A

P/B

2.0x56.2

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

30%5.3

RS 6M

-70%14.1

SMA 50/200

0.68x4.5

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-15%16.0

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$348M

P/E (Forward)

-4.4x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CMPX are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
CMPX	Compass Therapeutics, Inc.(you)	$348M	8	STRONG SELL
IVVD	Invivyd, Inc.	$333M	9	STRONG SELL
NMRA	Neumora Therapeutics, Inc.	$348M	10	STRONG SELL
LYEL	Lyell Immunopharma, Inc.	$393M	8	STRONG SELL
DMAC	DiaMedica Therapeutics Inc.	$332M	10	STRONG SELL
LXEO	Lexeo Therapeutics, Inc.	$399M	7	STRONG SELL
FBRX	Forte Biosciences, Inc.	$425M	10	STRONG SELL
LENZ	LENZ Therapeutics, Inc.	$251M	7	STRONG SELL
RGNX	REGENXBIO Inc.	$356M	1	STRONG SELL
OCGN	Ocugen, Inc.	$477M	9	STRONG SELL

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%

Compass Therapeutics, Inc. (CMPX) — Stock Score Summary

Compass Therapeutics, Inc. (CMPX) has a MoatMap StockRank of 8/100 based on Quality (39/100), Value (38/100), and Momentum (12/100) factor scores. The current signal is STRONG SELL. Compass Therapeutics is a clinical-stage oncology biotech with high cash burn. It does not possess the validated manufacturing scale or pricing power of a high-moat CDMO, failing our quality filters.

Key Financial Metrics

Price	$2.04
Market Cap	$348M
P/E (Forward)	-4.41
Price/Book	1.96
Return on Equity	-45.9%
Return on Invested Capital	-35.4%
Debt/Equity	5.25
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-30M

Compass Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Compass Therapeutics, Inc.’s (CMPX) StockRank?: MoatMap’s StockRank for Compass Therapeutics, Inc. (CMPX) is 8/100, with a Strong Sell signal. It is a composite of Quality (39), Value (38), and Momentum (12) factor ranks across MoatMap’s 19,000+ stock universe.
Does Compass Therapeutics, Inc. have an economic moat?: Compass Therapeutics, Inc. (CMPX) has a Quality factor score of 39/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Compass Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Compass Therapeutics, Inc. (CMPX) is Strong Sell, based on a StockRank of 8/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Compass Therapeutics, Inc. in?: Compass Therapeutics, Inc. (CMPX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).